RESUMO
The aim of our study was to evaluate validity of transcranial magnetic stimulation as evaluation tool of motor pathways condition dynamics in patients with gliomas and meningitis. There were included 91 patients: 40 children with aseptic meningitis, 26 matching age controls, 10 adults with gliomas and 16 matching controls. All patients underwent transcranial magnetic stimulation (TMS) before and after the treatment. TMS showed good tolerability in all groups. Significant improvement of central motor pathways conductivity (MEPs amplitudes) was seen in both groups. In meningitis group significant rising of functional state of motoneurons was seen as well. We propose that TMS proved to be effective evaluation tool of motor pathways condition dynamic in patients with gliomas and meningitis.
Assuntos
Glioma/diagnóstico , Meningite Asséptica/diagnóstico , Córtex Motor/fisiopatologia , Adolescente , Adulto , Criança , Vias Eferentes/fisiopatologia , Potencial Evocado Motor , Feminino , Glioma/diagnóstico por imagem , Glioma/fisiopatologia , Humanos , Masculino , Meningite Asséptica/diagnóstico por imagem , Meningite Asséptica/fisiopatologia , Pessoa de Meia-Idade , Estimulação Magnética Transcraniana/métodosRESUMO
Malignant glioma is the most frequently occurring primary brain tumor. Despite significant progress in the diagnostics and treatment of neoplastic diseases the prognosis for patients with III-IV grade gliomas, remains extremely unfavorable. Rapidly developing area in oncology is the employment of therapeutic viruses with natural or genetically engineered oncolytic activity. In the present study we demonstrated the oncolytic potential of a recombinant influenza A virus vector with impaired interferon antagonism function of NS1 protein in treatment of malignant glioma. Recombinant influenza A virus (HA-DS-GFP) expressing green fluorescent protein from the NS1 open reading frame was used as a model vector. HA-DS-GFP virus has shown infectivity towards glioma cells both in vitro, and in vivo (experimental glioma model in rats). Intratumoral inoculation of HA-DS-GFP resulted in a substantial inhibition or complete regression of tumor growth. Our data demonstrate that recombinant influenza vectors have promising potential in therapy of malignant gliomas.
Assuntos
Glioma/terapia , Vírus da Influenza A , Neoplasias Experimentais/terapia , Terapia Viral Oncolítica , Vírus Oncolíticos , Animais , Linhagem Celular Tumoral , Feminino , Glioma/genética , Glioma/metabolismo , Humanos , Neoplasias Experimentais/genética , Neoplasias Experimentais/metabolismo , Neoplasias Experimentais/patologia , RatosRESUMO
During continuous cultivation cell lines can lose a number of innate characteristics or acquire new ones. In this work we compared growth and phenotypic characteristics of human glioblastoma À172 and Ò98G lines from cell culture collection of Research Institute of Influenza of Ministry of Health of Russian Federation (St. Petersburg). The activity of genes encoding intracellular proteins that determine cell lines belonging to mesenchymal type, as well as several growth factor genes and extracellular matrix genes were estimated. Cell lines A172 and T98G varied in morphology and surface markers expression. A172 cells were characterized by higher expression of mesenchymal markers CD90, CD105, fibroblast activation protein, and tenascin C. Both cell lines showed high level of a2 smooth muscle actin expression. The obtained data indicating high activity of genes encoding major inductors of angiogenesis (VEGF, FGF2 (b), TGFb1) and thrombospondin-1 in foregoing cell lines are in agreement with published data. Reduction of fetal serum in culture medium from 10 to 5 % in both cell lines resulted in the increase of proportion of cells with surface antigens CD73 and CD105. Both A172 and T98G cell lines sustain the main features of glioblastomas and therefore can serve as research objects in investigation of this kind of neoplasms.
Assuntos
Antígenos de Diferenciação/biossíntese , Linhagem Celular Tumoral , Regulação Neoplásica da Expressão Gênica , Glioblastoma , Proteínas de Neoplasias/biossíntese , Linhagem Celular Tumoral/metabolismo , Linhagem Celular Tumoral/patologia , Glioblastoma/metabolismo , Glioblastoma/patologia , HumanosRESUMO
Mesenchymal stromal cells were isolated from the adipose tissue obtained during surgery for breast cancer and cultured under conditions of normal or low oxygen concentrations. In patients that had received a course of radiation and polychemotherapy prior to surgery, the proliferative potential of mesenchymal stromal cells was irreversibly disturbed. In patients receiving no therapy prior to surgery, the morphological, growth, phenotypic, and differentiation characteristics of mesenchymal stromal cells did not differ from the corresponding parameters of mesenchymal stromal cells from healthy donors. Culturing under hypoxic conditions increased adipogenic differentiation potencies of mesenchymal stromal cells from donors and patients.
Assuntos
Neoplasias da Mama/patologia , Células-Tronco Mesenquimais/patologia , Neoplasias da Mama/imunologia , Feminino , Humanos , ImunofenotipagemRESUMO
We investigated central motor pathways and central inhibition in patients with brain gliomas by transcranial magnetic stimulation (TMS). 10 glioma patients and 16 matching controls were enrolled. Central motor conduction time, MEP latencies and amplitudes and silent period were evaluated. In 90% glioma patients TMS parameters were abnormal, mostly MEP shapes and thresholds were affected. In 40% of the cases central inhibition in glioma affected hemisphere was abnormally high. We propose that TMS is safe and informative tool in glioma patients; central inhibition seems to be affected in some cases by the glioma presence in the hemisphere. One of the possible causes of that may be GABA system activation.
Assuntos
Neoplasias Encefálicas/fisiopatologia , Neoplasias Encefálicas/radioterapia , Vias Eferentes/fisiopatologia , Glioma/fisiopatologia , Glioma/radioterapia , Córtex Motor/fisiopatologia , Radioterapia Conformacional , Estimulação Magnética Transcraniana , Adulto , Neoplasias Encefálicas/metabolismo , Vias Eferentes/efeitos da radiação , Potencial Evocado Motor , Feminino , GABAérgicos/metabolismo , Glioma/metabolismo , Humanos , Masculino , Pessoa de Meia-Idade , Córtex Motor/metabolismoAssuntos
Neoplasias Encefálicas/patologia , Encefalite/patologia , Lesões Pré-Cancerosas , Formação Reticular/patologia , Formação Reticular/fisiopatologia , Animais , Neoplasias Encefálicas/fisiopatologia , Neoplasias do Tronco Encefálico/secundário , Neoplasias do Sistema Nervoso Central/patologia , Encefalite/fisiopatologia , Humanos , Lesões Pré-Cancerosas/patologia , Lesões Pré-Cancerosas/fisiopatologiaRESUMO
Examination including MRI (CT), PET with sodium 11C-butyrate (11C-SB) and 18fluorodeoxyglucose (18F-FDG) was carried out in 59 patients with continuing growth of malignant glioma. It was established that 11C-SB-PET is characterized by high sensitivity (94.1%) in detecting continuing growth as well as to differentiating it from necrosis. Our data were instrumental in prognosis and assaying metabolic levels in tumor (T/NT ratios) which are regarded as indices of accumulation (IA) of 18F-FDG-PET (FDG-IA) prior to conservative treatment. There were a direct correlation between metabolic activity of neoplasms and an inverse one with FDG-IA (r=-0.24).
Assuntos
Neoplasias Encefálicas/patologia , Neoplasias Encefálicas/terapia , Glioma/patologia , Glioma/terapia , Tomografia por Emissão de Pósitrons , Adulto , Idoso , Neoplasias Encefálicas/diagnóstico por imagem , Neoplasias Encefálicas/mortalidade , Radioisótopos de Carbono , Feminino , Fluordesoxiglucose F18 , Glioma/diagnóstico por imagem , Glioma/mortalidade , Humanos , Imageamento por Ressonância Magnética , Masculino , Pessoa de Meia-Idade , Tomografia por Emissão de Pósitrons/métodos , Valor Preditivo dos Testes , Compostos Radiofarmacêuticos , Tomografia Computadorizada por Raios X , Resultado do TratamentoRESUMO
Thirty-nine patients with malignant glioma of the brain were examined at the Center's Clinic. Tumor volume ranged 0.8-175.1 cu cm. Radionuclide diagnosis was obtained with the aid of single-photon emission tomography (E.Cam, Siemens). 99mTc-DTPA, 3-6 MBc/body, was injected intravenously. Smaller size of tumor and lower ratio of differentiated marker accumulation focus/contralateral area were registered in 34%. Simultaneously, a high index of the marker accumulation in the brain was reported, thus suggesting hyperimpermeability of the blood brain barrier. Another 26% revealed larger size of tumor and higher ratio of differentiated 99mTc-DTPA accumulation, likely due to lower impermeability of the blood brain barrier. Hence, use of single-photon emission tomography in diagnosis of malignant cerebral glioma provides a means of evaluating the level of the marker in a tumor node.
Assuntos
Neoplasias Encefálicas/diagnóstico por imagem , Neoplasias Encefálicas/terapia , Glioma/diagnóstico por imagem , Glioma/terapia , Pentetato de Tecnécio Tc 99m , Tomografia Computadorizada de Emissão de Fóton Único , Adulto , Idoso , Neoplasias Encefálicas/patologia , Quimioterapia Adjuvante , Feminino , Glioma/patologia , Humanos , Masculino , Pessoa de Meia-Idade , Valor Preditivo dos Testes , Compostos Radiofarmacêuticos , Radioterapia Adjuvante , Pentetato de Tecnécio Tc 99m/administração & dosagem , Pentetato de Tecnécio Tc 99m/metabolismo , Tomografia Computadorizada de Emissão de Fóton Único/métodos , Resultado do TratamentoRESUMO
We developed a new method of accelerated chemoimmunoradiotherapy for cerebral glioblastoma and evaluated the immediate effects. A single focal dose of 3Gy was administered once a day 5 times a week until the total focal dose of 51 Gy was reached. Chemoradiotherapy was followed by a course of biotherapy with recombinant interleukine-2 (roncoleukine). On administering a total dose of 10 million units, a course of chemoimmunotherapeutic support was given after a 2-week break. Vincristine 1 mg was injected on day 1 and nitrosourea preparations (lomustine 160 mg or carmustine 100 mg) on day 2. Later on, the same regimen of roncoleukine was used. Our method was followed by longer survival as compared with standard treatment (control) and use of incomplete course chemoimmunotherapy.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Neoplasias Encefálicas/tratamento farmacológico , Neoplasias Encefálicas/radioterapia , Glioblastoma/tratamento farmacológico , Glioblastoma/radioterapia , Imunoterapia/métodos , Interleucina-2/uso terapêutico , Adulto , Idoso , Neoplasias Encefálicas/cirurgia , Carmustina/administração & dosagem , Quimioterapia Adjuvante , Fracionamento da Dose de Radiação , Esquema de Medicação , Feminino , Glioblastoma/cirurgia , Humanos , Lomustina/administração & dosagem , Masculino , Pessoa de Meia-Idade , Período Pós-Operatório , Radioterapia Adjuvante , Proteínas Recombinantes/uso terapêutico , Análise de Sobrevida , Resultado do Tratamento , Vincristina/administração & dosagemRESUMO
Ductal cytometry provides data on cellular DNA and RNA levels and overall profile of specific proteins identifiable by monoclonal antibodies. Results of its long-term use in clinical and oncological research are presented. Application of dosage ranging 0.28-1.1 mGy/sec was followed by stable 1.8-2-fold increase in the myelokariocyte profile cbering DNA synthesis. Bone marrow proliferation did not increase until relatively low dosage was used. A study of combined effects of prolonged gamma irradiation and lead and cadmium ions on rat's hemopoiesis pointed to radiation as the sole causative factor when cadmium chloride was used. Hemopoietic characteristics came back to normal when a combination of lead acetate and ionizing radiation was used, as a result of the oppositely directed action of the two factors. Standard monoclonal antibodies should not be employed for evaluating immunological vigor of patients with malignant gliomas due to the presence of a specific pathological link in their immune system.
Assuntos
Pesquisa Biomédica , DNA de Neoplasias , Citometria de Fluxo , Hematopoese/efeitos dos fármacos , Hematopoese/efeitos da radiação , Academias e Institutos , Animais , Pesquisa Biomédica/tendências , Medula Óssea/efeitos dos fármacos , Medula Óssea/efeitos da radiação , Cloreto de Cádmio/farmacologia , DNA de Neoplasias/análise , Citometria de Fluxo/métodos , Citometria de Fluxo/estatística & dados numéricos , Raios gama , Órgãos Governamentais , Humanos , Compostos Organometálicos/farmacologia , RNA Neoplásico/análise , Radiação Ionizante , Dosagem Radioterapêutica , Federação RussaRESUMO
The paper discusses the data from dynamic follow-up of immunohistologically confirmed glioblastomas of the brain using proton magnetic resonance imaging (+H MRI) (25). Study was undertaken before and after therapy and resumed for 6-8 months after. Cholin concentration peaks and N-acetyl-aspartate decrease in gliomas appeared to be higher than those in anaplastic astrocytomas. Moreover, N-acetyl-aspartate peaks were obliterated by large necrotic areas in glioblastoma. Instead, lipid and lactate concentrations peaked thus suggesting pathological changes. A necrotic area developed in the course of radiochemotherapy involving peaks for wide profile of lipid and lactate concentrations coupled with lowered levels of other metabolites.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Neoplasias Encefálicas/tratamento farmacológico , Neoplasias Encefálicas/radioterapia , Espectroscopia de Ressonância Magnética , Prótons , Neoplasias Encefálicas/patologia , Quimioterapia Adjuvante , Feminino , Humanos , Espectroscopia de Ressonância Magnética/métodos , Masculino , Pessoa de Meia-Idade , Necrose , Radioterapia AdjuvanteRESUMO
Procedure of accelerated immunotherapy for cerebral glioma is presented. Large fractions of radiation ranged from 3 Gy, 5 times a week, to a total focal dose of 51 Gy. After accumulation of total doses of 18, 33 and 48 Gy, vincristine was injected intravenously. Urea derivatives were given on reaching 21, 36 and 51 Gy. Treatment with the immunomodulator roncoleukine was carried out on completion of radiotherapy. An evaluation of the immediate end results of accelerated immunotherapy showed improved survival as compared with standard treatment.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Neoplasias Encefálicas/terapia , Irradiação Craniana , Glioma/terapia , Fator Estimulador de Colônias de Granulócitos e Macrófagos/uso terapêutico , Fatores Imunológicos/uso terapêutico , Imunoterapia/métodos , Adulto , Idoso , Astrocitoma/terapia , Neoplasias Encefálicas/tratamento farmacológico , Neoplasias Encefálicas/imunologia , Neoplasias Encefálicas/radioterapia , Neoplasias Encefálicas/cirurgia , Quimioterapia Adjuvante , Fracionamento da Dose de Radiação , Feminino , Glioblastoma/terapia , Glioma/tratamento farmacológico , Glioma/imunologia , Glioma/radioterapia , Glioma/cirurgia , Humanos , Masculino , Pessoa de Meia-Idade , Compostos de Nitrosoureia/administração & dosagem , Período Pós-Operatório , Radioterapia Adjuvante , Proteínas Recombinantes , Análise de Sobrevida , Fatores de Tempo , Resultado do Tratamento , Vincristina/administração & dosagemRESUMO
The combiened effects of different dose rates (0.625 microGy/s - 1.1 mGy/s) of gamma-irradiation and of cuprum and of cadmium ions on the haematopoietic system of rats were studied. It was found that only low dose rates (0.625-10 microGy/s, summary doses 0.5-2.0 Gy) of gamma-irradiation yields in the increasing proliferative activity of bone marrow. The number of myelocariocytos in S-phase was increased at 1.5-1.8 times. In case of the treatment with both cadmium chloride and radiation the changes in proliferative activity of bone marrow are completely due to the radiation factor. Combination of cuprum acetate and ionizing radiation induce opposite effects providing formal normalization of the haematopoietic characteristic of bone marrow up to 3, 6 and 12 months after the end of the radiation and the chemical exposure of the animal.